JIPOAd
JIPOAd
PARP
ESID
  • Users Online: 120
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most popular articles (Since November 13, 2017)

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EDITORIAL
Being realistic and optimistic in curing cancer
Aung Naing
October-December 2018, 1(2):53-55
DOI:10.4103/JIPO.JIPO_20_18  
  2,626 457 7
REVIEW ARTICLES
Pneumonitis after precision oncology therapies: A concise review
Akash Jain, Vickie R Shannon, Ajay Sheshadri
July-September 2018, 1(1):26-37
DOI:10.4103/JIPO.JIPO_9_18  
  2,602 362 -
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Abdulrazzak Zarifa, Mohammed Salih, Juan Lopez-Mattei, Hun Ju Lee, Cezar Iliescu, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Elie Mouhayar, Joseph Kim, Peter Kim
October-December 2018, 1(2):68-77
DOI:10.4103/JIPO.JIPO_15_18  
  2,245 289 1
REVIEW ARTICLE
Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials
Haelee M Chin, David K Lai, Gerald S Falchook
January-March 2019, 2(1):10-16
DOI:10.4103/JIPO.JIPO_17_18  
  2,021 332 2
ORIGINAL ARTICLES
Erlotinib in patients with advanced non-small cell lung cancer in Middle Eastern population
Abdul Rahman Jazieh, Turki M Fayea, Mervat Mahrous, Tarek Darwish, Essam Fawzi, Ashwaq A Alolayan, Nagham Sheblaq, Mohammed Alkaiyat, Yosra Ali
July-September 2018, 1(1):19-25
DOI:10.4103/JIPO.JIPO_2_18  
  2,147 173 1
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang
July-September 2018, 1(1):7-18
DOI:10.4103/JIPO.JIPO_12_18  
  1,974 326 9
ORIGINAL ARTICLE
The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
Abdul Rahman Jazieh, Adda Bounedjar, Fouad Al Dayel, Shamayel Fahem, Arafat Tfayli, Kakil Rasul, Hassan Jaafar, Mohammad Jaloudi, Turki Al Fayea, Hatim Q Al Maghrabi, Hanaa Bamefleh, Khaled Al Kattan, Blaha Larbaoui, Taha Filali, Hamed Al Husaini, Yosra Ali, in collaboration with the Arab Collaborative Hematology Oncology Group (ACHOG)
January-March 2019, 2(1):4-7
DOI:10.4103/JIPO.JIPO_22_18  
  1,963 143 2
ORIGINAL ARTICLES
Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series
David D Stenehjem, Courtney C Cavalieri, Eric Swanson, Benjamin Solomon, Jonathan Whisenant, Dao Tran, John Weis, G Weldon Gilcrease, Sunil Sharma, Ignacio Garrido-Laguna
July-September 2018, 1(1):1-6
DOI:10.4103/JIPO.JIPO_5_18  
  1,754 191 -
REVIEW ARTICLES
Understanding the toxicity of cancer immunotherapies: Use of patient-reported outcomes
Tito R Mendoza
July-September 2018, 1(1):38-45
DOI:10.4103/JIPO.JIPO_10_18  
  1,599 256 -
Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs
Elena Cojocaru, Mariana Scaranti, Anna Minchom
April-June 2019, 2(2):23-35
DOI:10.4103/JIPO.JIPO_24_18  
  1,436 401 -
ORIGINAL RESEARCH
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing
Timothy J Looney, Dzifa Y Duose, Geoffrey Lowman, Elizabeth Linch, Joud Hajjar, Denise Topacio-Hall, Mingxuan Xu, Jianping Zheng, Anas Alshawa, Coya Tapia, Bettzy Stephen, Linghua Wang, Funda Meric-Bernstam, Lauren Miller, Alexander Glavin, Lifeng Lin, Jing Gong, Jeffrey Conroy, Carl Morrison, Fiona Hyland, Aung Naing
October-December 2019, 2(4):137-143
DOI:10.4103/JIPO.JIPO_16_19  
  1,696 96 1
REVIEW ARTICLES
Personalized cancer immunotherapy: Today's challenge and tomorrow's promise
Malaka Ameratunga, Wen Xu, Juanita Lopez
October-December 2018, 1(2):56-67
DOI:10.4103/JIPO.JIPO_13_18  
  1,574 204 -
EDITORIAL
Optimizing Precision Oncology and Immunotherapy Strategies: Moving into the Next Stage of Cancer Medicine
Phoebe Lewis, Timothy A Yap
January-March 2019, 2(1):1-3
DOI:10.4103/JIPO.JIPO_26_18  
  1,457 240 -
REVIEW ARTICLES
Should we design clinical trials differently in the era of cancer immunotherapy?
Chia-Chi Lin
April-June 2019, 2(2):36-39
DOI:10.4103/JIPO.JIPO_5_19  
  1,401 186 1
CASE REPORT
MET receptor amplification drives resistance to Anti-EGFR therapies
Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
October-December 2019, 2(4):152-155
DOI:10.4103/JIPO.JIPO_7_19  
  1,453 69 -
CASE REPORTS
Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel
October-December 2018, 1(2):78-81
DOI:DOI: 10.4103/JIPO.JIPO_7_18  
  1,323 158 -
EXPERT OPINION
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data
Katherine A Scilla, Alessandro Russo, Christian Rolfo
July-September 2019, 2(3):55-58
DOI:10.4103/JIPO.JIPO_13_19  
  1,375 100 -
EDITORIAL
Moonshot for precision medicine
Jordi Rodon
April-June 2019, 2(2):21-22
DOI:10.4103/JIPO.JIPO_4_19  
  1,304 165 -
ORIGINAL RESEARCH
Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast
Sara Simonetti, Nuria Dominguez, Analia Elguezabal, Francesco Pepe, Mariantonia Nacchio, Floriana Conticelli, Umberto Malapelle, Giancarlo Troncone, Lidia Sanchez, Xavier Guardia, Paolo Nuciforo, Luigi Insabato
October-December 2019, 2(4):130-136
DOI:10.4103/JIPO.JIPO_17_19  
  1,383 73 -
CASE REPORTS
Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab
Amulya Balagani, Muhammad H Arain, Ajay Sheshadri
July-September 2018, 1(1):49-52
DOI:10.4103/JIPO.JIPO_8_18  
  1,240 125 1
CASE REPORT
Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang
April-June 2019, 2(2):40-45
DOI:10.4103/JIPO.JIPO_18_18  
  1,128 185 -
CASE REPORTS
Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy
Macartney E Welborn, Shelby L Kubicki, Anisha B Patel
October-December 2018, 1(2):82-84
DOI:10.4103/JIPO.JIPO_11_18  
  1,108 142 1
REVIEW ARTICLES
Kaposi's sarcoma in the immunosuppressed
Nisha A Reddy, Steven R Mays, Omar Pacha
July-September 2019, 2(3):74-78
DOI:10.4103/JIPO.JIPO_10_19  
  1,141 94 -
SPECIAL ARTICLE
5th Annual immuno-oncology 360° conference: Spanning science and business to bring new therapies to patients
Marie Recine
April-June 2019, 2(2):46-51
DOI:10.4103/JIPO.JIPO_6_19  
  1,098 136 -
ORIGINAL RESEARCH
Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders
Mohsin Shah, Mazen N Jizzini, Imad E Majzoub, Aiham Qdaisat, Cielito C Reyes-Gibby, Sai-Ching Yeung
July-September 2019, 2(3):59-64
DOI:10.4103/JIPO.JIPO_11_19  
  1,092 118 -